Personalized tumor vaccines keep cancer in check
April 25, 2017
PSA Test: Reconsidering the Recommendation | BioPlus Specialty Pharmacy
April 25, 2017
Show all

Ocrevus Approval: A Quick Cheat Sheet 

A new medication for multiple sclerosis, Ocrevus (ocrelizumab), is now available to multiple sclerosis patients.

The multiple sclerosis (MS) community has been busy talking about the recently FDA-approved drug Ocrevus (ocrelizumab). It’s been proven to slow down the progression of the disease, but what else do we know about this much buzzed-about drug? Here are some quick facts about Ocrevus according to the Multiple Sclerosis Society.

When it was approved: March 28. Ocrevus is a drug used for the treatment of relapsing-remitting multiple sclerosis (RRMS) and the first treatment available for primary-progressive multiple sclerosis (PPMS).

How it’s taken: The drug is to be taken via an IV infusion every six months. The first dose is given in two stages a fortnight apart.

Who can take it: Ocrevus has not been tested on children and is only for the treatment of adults with PPMS and RRMS.

How it works: Ocrevus targets certain B-cells in the blood which are responsible for demyelination.

How do we know? Clinical trials with PPMS patients showed that those taking the drug experienced a 24 percent reduction in disease progression and a decrease in a number of brain lesions. Clinical trials with RRMS patients showed a 47 percent decrease in relapses compared to patients taking Rebif and up to 95 percent reduction in active inflammation.

How much it’ll cost: The yearly cost of Ocrevus treatment will be $65,000, which patients should be able to get covered by their medical insurance.

Read full article: Ocrevus Approval: A Quick Cheat Sheet – Multiple Sclerosis News Today

Read Full Article: Ocrevus Approval: A Quick Cheat Sheet – Multiple Sclerosis News Today

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.